FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136998531> ?p ?o ?g. }

• W3136998531 endingPage "1078" @default.
• W3136998531 startingPage "1071" @default.
• W3136998531 abstract "To compare the effects of Angiotensin Receptor-Neprilysin inhibitor (ARNI) on the clinical symptoms, echocardiographic parameters, and outcomes (cardiovascular death and hospitalization) in heart failure with reduced ejection fraction (HFrEF) and heart failure with mid-range ejection fraction (HFmrEF) patients with coronary heart disease and chronic kidney disease.A retrospective observational study was conducted from January 2018 to May 2019, with a follow-up period of 95.4 ± 57.8 days (8 months). Data from 127 patients were included.A statistically significant increase of 68.8% was observed in left ventricular ejection fraction (LVEF) in HFrEF patients compared to that in HFmrEF patients, with an increase of 27.2% at 8 months of follow-up. Sacubitril/valsartan significantly reduced left ventricular end-systolic volumes (LVESV) in HFrEF patients unlike in HFmrEF patients. The decrease in LVESV was 28.8% in HFrEF patients and 17.1% in HFmrEF patients. A significant reduction in the prevalence of severe secondary mitral regurgitation (EROA > 0.4 cm2) was observed in HFrEF compared to that in HFmrEF patients with the use of sacubitril/valsartan. A reduction of 15.6% was observed in HFrEF patients, whereas a reduction of 7.1% was observed in HFmrEF patients. Improvement in functional classification (NYHA) was observed during follow-up. The prevalence of (NYHA III) reduced from 50% to 15.7% in HFrEF patients, whereas a reduction from 21.1% to 8.8% was observed in HFmrEF patients. There was a significant reduction in NT-proBNP in HFrEF patients compared to that in HFmrEF patients. A reduction of 52% was observed in HFrEF patients, whereas a reduction of 28.7% was observed in HFmrEF pateints. Sacubitril/valsartan reduced primary endpoint events in both groups. The prevalence of HF-related hospitalization was higher in HFrEF than in HFmrEF patients: 12.1% vs 7.5%, respectively. The prevalence of CV death in HFrEF vs HFmrEF patients was 3.7% vs 0.5%, respectively. Cardiovascular (CV) death was higher in patients with atrial fibrillation in both groups.Sacubitril/valsartan significantly improved morphofunctional remodeling parameters and clinical symptoms in HFrEF patients than in HFmrEF patients." @default.
• W3136998531 created "2021-03-29" @default.
• W3136998531 creator A5015470446 @default.
• W3136998531 creator A5019085796 @default.
• W3136998531 creator A5020468164 @default.
• W3136998531 creator A5034360901 @default.
• W3136998531 creator A5050918549 @default.
• W3136998531 creator A5051626544 @default.
• W3136998531 creator A5063734383 @default.
• W3136998531 creator A5080753341 @default.
• W3136998531 date "2021-04-20" @default.
• W3136998531 modified "2023-10-03" @default.
• W3136998531 title "Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease" @default.
• W3136998531 cites W2014277401 @default.
• W3136998531 cites W2427094903 @default.
• W3136998531 cites W2518722683 @default.
• W3136998531 cites W2597217516 @default.
• W3136998531 cites W2598474547 @default.
• W3136998531 cites W2750209553 @default.
• W3136998531 cites W2775355990 @default.
• W3136998531 cites W2888004458 @default.
• W3136998531 cites W2915228171 @default.
• W3136998531 cites W2917132355 @default.
• W3136998531 cites W2920941132 @default.
• W3136998531 cites W2920977137 @default.
• W3136998531 cites W2921101918 @default.
• W3136998531 cites W2922039016 @default.
• W3136998531 cites W2924044641 @default.
• W3136998531 cites W2924969039 @default.
• W3136998531 cites W2932054148 @default.
• W3136998531 cites W2935786742 @default.
• W3136998531 cites W2935803651 @default.
• W3136998531 cites W2936272451 @default.
• W3136998531 cites W2940903529 @default.
• W3136998531 cites W2942088901 @default.
• W3136998531 cites W2943332165 @default.
• W3136998531 cites W2944174440 @default.
• W3136998531 cites W2944905490 @default.
• W3136998531 cites W2945205947 @default.
• W3136998531 cites W2945543541 @default.
• W3136998531 cites W2945851042 @default.
• W3136998531 cites W3016912776 @default.
• W3136998531 cites W3036490372 @default.
• W3136998531 cites W4211258939 @default.
• W3136998531 doi "https://doi.org/10.1080/03007995.2021.1908243" @default.
• W3136998531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33764230" @default.
• W3136998531 hasPublicationYear "2021" @default.
• W3136998531 type Work @default.
• W3136998531 sameAs 3136998531 @default.
• W3136998531 citedByCount "3" @default.
• W3136998531 countsByYear W31369985312022 @default.
• W3136998531 countsByYear W31369985312023 @default.
• W3136998531 crossrefType "journal-article" @default.
• W3136998531 hasAuthorship W3136998531A5015470446 @default.
• W3136998531 hasAuthorship W3136998531A5019085796 @default.
• W3136998531 hasAuthorship W3136998531A5020468164 @default.
• W3136998531 hasAuthorship W3136998531A5034360901 @default.
• W3136998531 hasAuthorship W3136998531A5050918549 @default.
• W3136998531 hasAuthorship W3136998531A5051626544 @default.
• W3136998531 hasAuthorship W3136998531A5063734383 @default.
• W3136998531 hasAuthorship W3136998531A5080753341 @default.
• W3136998531 hasConcept C126322002 @default.
• W3136998531 hasConcept C164705383 @default.
• W3136998531 hasConcept C2775999527 @default.
• W3136998531 hasConcept C2776754050 @default.
• W3136998531 hasConcept C2777387769 @default.
• W3136998531 hasConcept C2778198053 @default.
• W3136998531 hasConcept C2778653478 @default.
• W3136998531 hasConcept C71924100 @default.
• W3136998531 hasConcept C78085059 @default.
• W3136998531 hasConcept C84393581 @default.
• W3136998531 hasConceptScore W3136998531C126322002 @default.
• W3136998531 hasConceptScore W3136998531C164705383 @default.
• W3136998531 hasConceptScore W3136998531C2775999527 @default.
• W3136998531 hasConceptScore W3136998531C2776754050 @default.
• W3136998531 hasConceptScore W3136998531C2777387769 @default.
• W3136998531 hasConceptScore W3136998531C2778198053 @default.
• W3136998531 hasConceptScore W3136998531C2778653478 @default.
• W3136998531 hasConceptScore W3136998531C71924100 @default.
• W3136998531 hasConceptScore W3136998531C78085059 @default.
• W3136998531 hasConceptScore W3136998531C84393581 @default.
• W3136998531 hasFunder F4320322735 @default.
• W3136998531 hasIssue "7" @default.
• W3136998531 hasLocation W31369985311 @default.
• W3136998531 hasLocation W31369985312 @default.
• W3136998531 hasOpenAccess W3136998531 @default.
• W3136998531 hasPrimaryLocation W31369985311 @default.
• W3136998531 hasRelatedWork W2604998822 @default.
• W3136998531 hasRelatedWork W2805169473 @default.
• W3136998531 hasRelatedWork W2948540269 @default.
• W3136998531 hasRelatedWork W2969101984 @default.
• W3136998531 hasRelatedWork W3034576414 @default.
• W3136998531 hasRelatedWork W4229334242 @default.
• W3136998531 hasRelatedWork W4289711873 @default.
• W3136998531 hasRelatedWork W4296179117 @default.
• W3136998531 hasRelatedWork W4319600715 @default.
• W3136998531 hasRelatedWork W4324019008 @default.
• W3136998531 hasVolume "37" @default.

• next